Navigation Links
AEterna Zentaris Receives US$5.5 Million from Institutional Investors
Date:10/24/2009

QUEBEC CITY, Oct. 23 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), (the "Company") a global biopharmaceutical company focused on endocrine therapy and oncology, announced today that it has completed its previously announced registered direct offering of US$5.5 million of units comprised of common shares and common share purchase warrants to certain institutional investors. AEterna Zentaris received net proceeds of approximately US$5.1 million after deducting placement agent fees and other offering expenses. All of the common shares and warrants were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be used for general corporate purposes, including clinical development of the Company's leading compounds.

Juergen Engel, Ph. D., President and CEO of AEterna Zentaris stated, "We are very pleased with this vote of confidence from targeted specialized institutional investors. In addition, completing this financing provides us with additional funds that will help us to continue to further strengthen and advance our promising pipeline."

As of October 23, 2009 and after issuing 4,583,335 common shares at the closing of the offering, the Company had 63,089,954 common shares issued and outstanding without giving effect to or assuming the exercise of any outstanding warrants.

A shelf registration statement relating to the common shares and warrants issued in the offering (and the common shares issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC") and has been declared effective. A prospectus supplement relating to the offering was filed with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from AEterna Zentaris Inc., 1405 du Parc-Technologique Bouleva
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Patrick Kennedy Joins with State Biotech Leaders ... in Research and Development while Boosting Rhode ... ,, PROVIDENCE, R.I., Dec. 14 /PRNewswire-USNewswire/ ... leaders in research, medicine and biotechnology gathered ... to discuss the importance of medical innovation ...
(Date:12/14/2009)... 14 Decision Resources, one of the ... and healthcare issues, finds that, owing to the ... drug market will increase more than sevenfold from ... 2018 in the United States, France, Germany, Italy, ... new Pharmacor report entitled Atrial Fibrillation ...
(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused ... therapeutics for cardiovascular and muscle disease, today announced ... plays a crucial role in the progression of ... and in neuromuscular synaptic regeneration in mice. ... of the journal Science , reveal miR-206 ...
(Date:12/11/2009)... Dec. 11 Marrone Bio Innovations (MBI) ... management team. Mr. Chris Hildreth joined MBI as ... responsible for expanding all commercial aspects of the ... Dr. Kin Sing (Ray) Lam joined MBI as ... company,s development efforts in scaling its broad pipeline ...
Breaking Biology Technology:Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Marrone Bio Innovations Announces Two New Executive Appointments 2Marrone Bio Innovations Announces Two New Executive Appointments 3
... OSLO, September 23 Affitech AS, the ... it has accomplished the,second milestone in its ... fully human recombinant antibodies against an unnamed ... (Molecule Based Antibody,Screening) system that included its ...
... HOUSTON, Sept. 22, 2008 -- Chemists at Rice University ... nanorods -- tiny, wand-like nanoparticles that are being studied ... as diagnosing disease and improving electronic viewscreens. , "The ... synthetic methods is only about 20 percent," said lead ...
... KNDL ), a,leading, global full-service clinical research organization, ... PharmD, will,participate in the annual UBS Global Life ... Grand Hyatt New York, Park Avenue at Grand,Central, ... is,scheduled for Wednesday, September 24 at 9:30 a.m. ...
Other Biology Technology:Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration 2Purifying nanorods: Big success with tiny cleanup 2
(Date:12/13/2009)... Scientists have resolved a question about how a ... works using biosensors that reveal previously hidden components ... Although delusions and hallucinations characterize the illness, people ... recall information in a particular order, difficulties that ... or function well, said Lee Schroeder, a student ...
(Date:12/13/2009)... associated with the health of the human lung. The ... 63 centres in Europe and Australia sheds new light ... new findings provide hope for better treatment for lung ... In the past it has been difficult to develop ... health of the lung are not completely understood. It,s ...
(Date:12/11/2009)... ROUGE, LAKeeping with the global "green" trend, ... education lessons to enhance students, science knowledge. ... into the curriculum raises not just science ... scores in other subject areas. Naturally, educators ... integrate these relevant lessons into the classroom ...
Breaking Biology News(10 mins):New biosensors reveal workings of anti-psychotic drugs in the living brain 2New genes for lung disease discovered 2Students learn environmental stewardship, improve science scores 2Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 1Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 2Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 3Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 4Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 5Patients Taking VIMOVO 28TM 29 Showed a Decrease in Incidence of NSAID Associated Ulcers 5553 1Patients Taking VIMOVO 28TM 29 Showed a Decrease in Incidence of NSAID Associated Ulcers 5553 2Patients Taking VIMOVO 28TM 29 Showed a Decrease in Incidence of NSAID Associated Ulcers 5553 3Patients Taking VIMOVO 28TM 29 Showed a Decrease in Incidence of NSAID Associated Ulcers 5553 4Patients Taking VIMOVO 28TM 29 Showed a Decrease in Incidence of NSAID Associated Ulcers 5553 5PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 1PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 2PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 3PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 4PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 5
... UT Southwestern Medical Center at Dallas,researchers have found ... mice,to fight against amyloid proteins that cause the ... scientists have examined the possibility of using a,protein-based ... in its,early stages. UT Southwestern researchers have created ...
... the quantity of a certain type of immune cell ... a bone marrow stem cell transplant will successfully restore ... a child. This research, by investigators at St. Jude ... , This finding could help physicians predict whether children ...
... among paleontologists states that when dinosaurs died and ... were essentially transformed into "rocks" through a gradual ... research by a North Carolina State University paleontologist, ... , Dr. Mary Schweitzer, assistant professor of paleontology ...
Other Biology News:Gene vaccine for Alzheimer's disease shows promising results 2Circles Of DNA Might Help Predict Success Of Stem Cell Transplantation 2Circles Of DNA Might Help Predict Success Of Stem Cell Transplantation 3Circles Of DNA Might Help Predict Success Of Stem Cell Transplantation 4NC State scientist finds soft tissue in T. rex bones 2
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
Each Yeast-GFP clone represents an individual S. cerevisiae strain containing an open reading frame with a C-terminal Aequorea Victoria GFP (S65T) fusion tag....
... protein analysis can be used for the identification ... and/or monitor renal and other diseases. Due to ... in large amounts, it provides an attractive alternative ... disease biomarkers. The ProteoSpin Urine Protein Concentration ...
Biology Products: